The following are the catalysts for AVXL, likely to happen before Jul. 2021 __________________________________________________________
1. Complete data ANAVEX®2-73 U.S. Rett syndrome Phase 2 study –expected Q2 2021
2. Complete data ANAVEX®2-73 Parkinson’s disease dementia (PDD) Phase 2 study –expected Q2 2021
3. Top-line data AVATAR: Potentially pivotal Phase 2/3 adult RTT clinical trial –expected mid 2021
4. Top-line data Phase 1 ANAVEX®3-71 clinical trial –expected mid 2021
__________________________________________________________
BTW, C Wainwright & Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and raises the price target from $17 to $25.